[{"id":"2cd939b3-0ad5-4da7-9783-177794412b1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01943851","created_at":"2021-01-18T08:48:17.616Z","updated_at":"2024-07-02T16:36:30.033Z","phase":"Phase 2","brief_title":"A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies","source_id_and_acronym":"NCT01943851","lead_sponsor":"GlaxoSmithKline","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC overexpression • CD20 expression","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e molibresib (GSK525762)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 05/14/2014","start_date":" 05/14/2014","primary_txt":" Primary completion: 04/30/2020","primary_completion_date":" 04/30/2020","study_txt":" Completion: 04/30/2020","study_completion_date":" 04/30/2020","last_update_posted":"2021-05-19"},{"id":"605feb5a-a612-4396-ba99-5fad946a9ff5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04116359","created_at":"2021-01-18T20:07:15.394Z","updated_at":"2024-07-02T16:36:40.639Z","phase":"Phase 1/2","brief_title":"Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma","source_id_and_acronym":"NCT04116359","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRD4 • NUTM1","pipe":"","alterations":" ","tags":["BRD4 • NUTM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • etoposide IV • molibresib (GSK525762)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/18/2020","start_date":" 09/18/2020","primary_txt":" Primary completion: 09/18/2020","primary_completion_date":" 09/18/2020","study_txt":" Completion: 09/18/2020","study_completion_date":" 09/18/2020","last_update_posted":"2020-09-28"},{"id":"2cc422f9-bbf0-49cc-8e87-efe44078158e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03702036","created_at":"2021-04-16T05:53:06.992Z","updated_at":"2024-07-02T16:36:46.062Z","phase":"","brief_title":"Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma","source_id_and_acronym":"NCT03702036","lead_sponsor":"GlaxoSmithKline","biomarkers":" NUTM1","pipe":"","alterations":" ","tags":["NUTM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e molibresib (GSK525762)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2020-04-13"},{"id":"ed89a3b8-b73e-4ee4-aac0-61619bfbd29f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01587703","created_at":"2021-01-18T06:46:16.022Z","updated_at":"2024-07-02T16:36:48.650Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers","source_id_and_acronym":"NCT01587703","lead_sponsor":"GlaxoSmithKline","biomarkers":" ER • MYCN • NUTM1","pipe":" | ","alterations":" ER positive • MYCN amplification","tags":["ER • MYCN • NUTM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e molibresib (GSK525762)"],"overall_status":"Completed","enrollment":" Enrollment 196","initiation":"Initiation: 03/28/2012","start_date":" 03/28/2012","primary_txt":" Primary completion: 04/13/2018","primary_completion_date":" 04/13/2018","study_txt":" Completion: 07/29/2019","study_completion_date":" 07/29/2019","last_update_posted":"2020-03-16"},{"id":"b54409dc-6ce8-465c-838e-5c152a25bdbb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03266159","created_at":"2021-03-26T09:18:25.614Z","updated_at":"2024-07-02T16:37:15.706Z","phase":"Phase 2","brief_title":"A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors","source_id_and_acronym":"NCT03266159","lead_sponsor":"GlaxoSmithKline","biomarkers":" KRAS • NRAS • HRAS • NF1 • CCL2","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • NF1 mutation • HRAS mutation","tags":["KRAS • NRAS • HRAS • NF1 • CCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • NF1 mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • molibresib (GSK525762)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/27/2017","start_date":" 11/27/2017","primary_txt":" Primary completion: 08/19/2020","primary_completion_date":" 08/19/2020","study_txt":" Completion: 08/19/2020","study_completion_date":" 08/19/2020","last_update_posted":"2017-12-08"}]